1. Home
  2. DSGN vs RDCM Comparison

DSGN vs RDCM Comparison

Compare DSGN & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • RDCM
  • Stock Information
  • Founded
  • DSGN 2017
  • RDCM 1985
  • Country
  • DSGN United States
  • RDCM Israel
  • Employees
  • DSGN N/A
  • RDCM N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • RDCM Computer peripheral equipment
  • Sector
  • DSGN Health Care
  • RDCM Technology
  • Exchange
  • DSGN Nasdaq
  • RDCM Nasdaq
  • Market Cap
  • DSGN 208.9M
  • RDCM 203.7M
  • IPO Year
  • DSGN 2021
  • RDCM 1997
  • Fundamental
  • Price
  • DSGN $5.74
  • RDCM $13.35
  • Analyst Decision
  • DSGN
  • RDCM Strong Buy
  • Analyst Count
  • DSGN 0
  • RDCM 1
  • Target Price
  • DSGN N/A
  • RDCM $18.00
  • AVG Volume (30 Days)
  • DSGN 201.9K
  • RDCM 52.5K
  • Earning Date
  • DSGN 11-06-2025
  • RDCM 11-12-2025
  • Dividend Yield
  • DSGN N/A
  • RDCM N/A
  • EPS Growth
  • DSGN N/A
  • RDCM 79.61
  • EPS
  • DSGN N/A
  • RDCM 0.56
  • Revenue
  • DSGN N/A
  • RDCM $66,334,000.00
  • Revenue This Year
  • DSGN N/A
  • RDCM $18.07
  • Revenue Next Year
  • DSGN N/A
  • RDCM $11.52
  • P/E Ratio
  • DSGN N/A
  • RDCM $23.90
  • Revenue Growth
  • DSGN N/A
  • RDCM 18.18
  • 52 Week Low
  • DSGN $2.60
  • RDCM $9.81
  • 52 Week High
  • DSGN $7.77
  • RDCM $15.98
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 43.44
  • RDCM 39.89
  • Support Level
  • DSGN $6.01
  • RDCM $13.46
  • Resistance Level
  • DSGN $7.21
  • RDCM $14.16
  • Average True Range (ATR)
  • DSGN 0.62
  • RDCM 0.54
  • MACD
  • DSGN -0.12
  • RDCM -0.12
  • Stochastic Oscillator
  • DSGN 3.65
  • RDCM 0.00

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About RDCM Radcom Ltd.

Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.

Share on Social Networks: